← Leaderboards
Otto O Yang
University Of California Los Angeles
$29,888,904
Attributed
$37,469,610
Total exposure
26
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,469,610 · 26
By mechanism
R01$17,883,854 · 6
U01$4,348,163 · 1
R21$3,852,311 · 9
P30$3,385,348 · 1
T32$2,822,604 · 2
U19$2,311,499 · 2
Top collaborators
- Peter A Anton5 shared
- Scott G Kitchen5 shared
- Roger Detels4 shared
- Otoniel Martinez-Maza4 shared
- Risa M. Hoffman3 shared
- Karin Nielsen3 shared
- William M Gelbart2 shared
- Robert Damoiseaux1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Xiaofeng Zhou$2,882,296
- David T Wong$54,826,713
- Martha J Lewis$1,777,535
- Anh D Le$4,956,118
- Shen Hu$531,923
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionCellsHiv-1ViralPersonsResponseIn VivoImmuneProteinsViremiaAntiviral AgentsAreaSuccessPathogenesisMutationVirusT-LymphocyteCd8b1 GeneEpitopesCytotoxic T-LymphocytesInterestPreventIn VitroImmunity
Grant awards (98)
Core B -Developmental Core$530,574
P30 · FY2025 · AI · contact PI
Harnessing the Pathogenesis of CMV Against HIV$467,055
R01 · FY2025 · AI · contact PI
Small Molecule Inhibitors Against HPV-Induced Orophageal Cancers$433,125
R21 · FY2025 · DE · contact PI
Addressing Evolving Infectious Threats$420,919
T32 · FY2025 · AI · contact PI
In vivo CAR-T-cell HIV therapy using in vitro reconstituted virus-like particles$226,772
R21 · FY2025 · AI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$776,131
R01 · FY2024 · AI · contact PI
Core B -Developmental Core$494,215
P30 · FY2024 · AI · contact PI
Harnessing the Pathogenesis of CMV Against HIV$467,055
R01 · FY2024 · AI · contact PI
Addressing Evolving Infectious Threats$405,108
T32 · FY2024 · AI · contact PI
Mucosal B-cell aging in PLWH$392,709
R56 · FY2024 · AG
In vivo CAR-T-cell HIV therapy using in vitro reconstituted virus-like particles$196,875
R21 · FY2024 · AI
Core B -Developmental Core$769,209
P30 · FY2023 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2023 · AI · contact PI
Addressing Evolving Infectious Threats$372,099
T32 · FY2023 · AI · contact PI
Viral Immunology Core$340,174
U19 · FY2023 · AI · contact PI
Core B -Developmental Core$166,547
P30 · FY2023 · AI · contact PI
Core B -Developmental Core$1,424,803
P30 · FY2022 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2022 · AI · contact PI
Viral Immunology Core$350,167
U19 · FY2022 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2021 · AI · contact PI
Viral Immunology Core$365,550
U19 · FY2021 · AI · contact PI
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir$336,819
P01 · FY2021 · AI · contact PI
Dual CMV and HIV CARs for Cure of HIV$234,000
R21 · FY2021 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2020 · AI · contact PI
Viral Immunology Core$351,000
U19 · FY2020 · AI · contact PI
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir$338,359
P01 · FY2020 · AI · contact PI
Dual CMV and HIV CARs for Cure of HIV$195,000
R21 · FY2020 · AI · contact PI
Los Angeles CRS for the MACS/WIHS Combined Cohort Study$46,610
U01 · FY2020 · HL
Los Angeles CRS for the MACS/WIHS Combined Cohort Study$3,900,000
U01 · FY2019 · HL
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir$346,249
P01 · FY2019 · AI · contact PI
Los Angeles CRS for the MACS/WIHS Combined Cohort Study$329,538
U01 · FY2019 · HL
Chimeric Broadly Neutralizing Anti-HIV Antibodies$195,000
R21 · FY2019 · AI · contact PI
Viral Immunology Core$140,452
U19 · FY2019 · AI · contact PI
Los Angeles CRS for the MACS/WIHS Combined Cohort Study$72,015
U01 · FY2019 · HL
Dissection of HIV-1 CTL Escape Pathways$385,000
R01 · FY2018 · DE · contact PI
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir$350,801
P01 · FY2018 · AI · contact PI
Chimeric Broadly Neutralizing Anti-HIV Antibodies$233,750
R21 · FY2018 · AI · contact PI
Viral Immunology Core$144,203
U19 · FY2018 · AI · contact PI
Topical Microbicides: Targeted Intracellular Delivery$558,194
R01 · FY2017 · AI · contact PI
Dissection of HIV-1 CTL Escape Pathways$416,803
R01 · FY2017 · DE · contact PI
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir$354,199
P01 · FY2017 · AI · contact PI
CD4 T Cell Differentiation and Susceptibility to HIV-Specific CTL Killing$231,000
R21 · FY2017 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING$213,969
T32 · FY2017 · AI · contact PI
Viral Immunology Core$207,272
U19 · FY2017 · AI · contact PI
Topical Microbicides: Targeted Intracellular Delivery$567,742
R01 · FY2016 · AI · contact PI
Dissection of HIV-1 CTL Escape Pathways$439,521
R01 · FY2016 · DE · contact PI
Viral Immunology Core$202,916
U19 · FY2016 · AI · contact PI
CD4 T Cell Differentiation and Susceptibility to HIV-Specific CTL Killing$192,500
R21 · FY2016 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING$158,007
T32 · FY2016 · AI · contact PI
Topical Microbicides: Targeted Intracellular Delivery$581,481
R01 · FY2015 · AI · contact PI
Dissection of HIV-1 CTL Escape Pathways$439,521
R01 · FY2015 · DE · contact PI
Viral Immunology Core$209,765
U19 · FY2015 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING$204,900
T32 · FY2015 · AI · contact PI
Functional Assessment of CTL Anergy in HIV Infection$192,500
R21 · FY2015 · AI · contact PI
Dissection of HIV-1 CTL Escape Pathways$22,718
R01 · FY2015 · DE · contact PI
Topical Microbicides: Targeted Intracellular Delivery$598,312
R01 · FY2014 · AI · contact PI
Dissection of HIV-1 CTL Escape Pathways$385,000
R01 · FY2014 · DE · contact PI
Functional Assessment of CTL Anergy in HIV Infection$231,000
R21 · FY2014 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)$228,458
T32 · FY2014 · AI · contact PI
Bio-Nanoparticles for HIV Antigen Delivery$192,500
R21 · FY2014 · AI · contact PI
Bio-Nanoparticles for HIV Antigen Delivery$231,000
R21 · FY2013 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)$224,631
T32 · FY2013 · AI · contact PI
HIV-1 Escape from Inhibition by Cytotoxic T Lymphocytes$403,787
R01 · FY2012 · AI · contact PI
Mechanistic Studies of HIV-exposed Seronegative Individuals$361,695
R56 · FY2012 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)$138,245
T32 · FY2012 · AI · contact PI
Identifying and closing gaps in TCR coverage of HIV-1 escape$385,000
R56 · FY2011 · AI · contact PI
HIV-1 Escape from Inhibition by Cytotoxic T Lymphocytes$376,869
R01 · FY2011 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$373,909
R01 · FY2011 · AI · contact PI
Addressing Intra-/Inter-Clade Diversity in HIV Vaccine Design by Immune Focusing$255,564
R21 · FY2011 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)$229,689
T32 · FY2011 · AI · contact PI
HIV-1 Escape from Inhibition by Cytotoxic T Lymphocytes$62,730
R01 · FY2011 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$383,300
R01 · FY2010 · AI · contact PI
HIV-1 Escape from Inhibition by Cytotoxic T Lymphocytes$380,675
R01 · FY2010 · AI · contact PI
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)$226,579
T32 · FY2010 · AI · contact PI
Addressing Intra-/Inter-Clade Diversity in HIV Vaccine Design by Immune Focusing$192,451
R21 · FY2010 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$441,264
R01 · FY2009 · AI · contact PI
HIV-1 Escape from Inhibition by Cytotoxic T Lymphocytes$388,300
R01 · FY2009 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$256,000
R01 · FY2009 · AI · contact PI
HIV-1 Escape from Inhibition by Cytotoxic T Lymphocytes$394,240
R01 · FY2008 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$377,685
R01 · FY2008 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$47,428
R01 · FY2008 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$385,000
R01 · FY2007 · AI · contact PI
HIV-1 Excape from Inhibiton by Cytotoxic T Lymphocytes$361,494
R01 · FY2007 · AI · contact PI
Mucosal and Peripheral NK-T Cells in HIV Infection$187,524
R21 · FY2007 · AI · contact PI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$387,804
R01 · FY2006 · AI · contact PI
HIV-1 Excape from Inhibiton by Cytotoxic T Lymphocytes$372,291
R01 · FY2006 · AI · contact PI
Mucosal and Peripheral NK-T Cells in HIV Infection$231,750
R21 · FY2006 · AI · contact PI
HIV-1 Excape from Inhibiton by Cytotoxic T Lymphocytes$381,250
R01 · FY2005 · AI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$343,125
R01 · FY2005 · AI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$50,138
R01 · FY2005 · AI
HIV-1 Excape from Inhibiton by Cytotoxic T Lymphocytes$381,250
R01 · FY2004 · AI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$343,125
R01 · FY2004 · AI
HIV-1 Excape from Inhibiton by Cytotoxic T Lymphocytes$381,250
R01 · FY2003 · AI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$343,125
R01 · FY2003 · AI
Immune Pressure on HIV-1 Nef by Cytotoxic T Lymphocytes$343,125
R01 · FY2002 · AI
HIV-1 ESCAPE FROM INHIBITION BY CYTOTOXIC T LYMPHOCYTES$256,338
R01 · FY2002 · AI
HIV-1 ESCAPE FROM INHIBITION BY CYTOTOXIC T LYMPHOCYTES$248,871
R01 · FY2001 · AI
HIV-1 ESCAPE FROM INHIBITION BY CYTOTOXIC T LYMPHOCYTES$241,624
R01 · FY2000 · AI